Javascript must be enabled to continue!
Characterization and stability analysis of metformin HCl microcapsules formulated by complex coacervation technique
View through CrossRef
Objective: Metformin hydrochloride possesses a shorter sort of biological half-life of 1.5–1.6 h with having the absolute type of bioavailability that ranges between 50-60%, the moment it is administered orally. Reduced GIT disturbances and low bioavailability can be optimized by developing microencapsulation of metformin that could prove beneficial. Method: Paraffin oil had been used in obtaining specific types of primary emulsions, whereas the material that was used in the coating of microencapsulation had been identified as sodium alginate. In the process of complex coacervation, a substance known as Tween 20 was used as a surfactant in enhancing the stability of W/O/W double emulsion. Five different formulations with different concentrations of sodium alginate were tested. Result: Metformin's microencapsulation inside certain types of optimized atmosphere tends to ensure the specific size of 1 μm of microcapsules in a combined form, and encapsulation efficiency reaches up to 84%. FTIR measurements have been used to determine the interaction between drug and polymer. The qualitative analysis result from FTIR ensures that the quality and effectiveness of the drug have been preserved. A calibration curve was used to estimate drug conc. from dissolution samples and kinetic analysis demonstrated anomalous release pattern. The test for drug content yielded ˃95% of concentration. Conclusion: Results extracted tend to tell us that specific complex coacervation that is using sodium alginate in wall material was a viable method that is used in the microencapsulation process of metformin hydrochloride.
AMMANIF Academic Publisher
Title: Characterization and stability analysis of metformin HCl microcapsules formulated by complex coacervation technique
Description:
Objective: Metformin hydrochloride possesses a shorter sort of biological half-life of 1.
5–1.
6 h with having the absolute type of bioavailability that ranges between 50-60%, the moment it is administered orally.
Reduced GIT disturbances and low bioavailability can be optimized by developing microencapsulation of metformin that could prove beneficial.
Method: Paraffin oil had been used in obtaining specific types of primary emulsions, whereas the material that was used in the coating of microencapsulation had been identified as sodium alginate.
In the process of complex coacervation, a substance known as Tween 20 was used as a surfactant in enhancing the stability of W/O/W double emulsion.
Five different formulations with different concentrations of sodium alginate were tested.
Result: Metformin's microencapsulation inside certain types of optimized atmosphere tends to ensure the specific size of 1 μm of microcapsules in a combined form, and encapsulation efficiency reaches up to 84%.
FTIR measurements have been used to determine the interaction between drug and polymer.
The qualitative analysis result from FTIR ensures that the quality and effectiveness of the drug have been preserved.
A calibration curve was used to estimate drug conc.
from dissolution samples and kinetic analysis demonstrated anomalous release pattern.
The test for drug content yielded ˃95% of concentration.
Conclusion: Results extracted tend to tell us that specific complex coacervation that is using sodium alginate in wall material was a viable method that is used in the microencapsulation process of metformin hydrochloride.
Related Results
Abstract 2765: Metformin represses cancer cells via alternate pathways in N-Cadherin wild-type and N-Cadherin-deficient cells
Abstract 2765: Metformin represses cancer cells via alternate pathways in N-Cadherin wild-type and N-Cadherin-deficient cells
Abstract
BACKGROUND
Metformin, one of the most commonly used medications for treatment of type 2 diabetes, has emerged as a potential anticancer agent...
Abstract PO1-05-11: Efficacy of metformin as adjunctive therapy in patients with de novo metastatic breast cancer: a retrospective cohort study
Abstract PO1-05-11: Efficacy of metformin as adjunctive therapy in patients with de novo metastatic breast cancer: a retrospective cohort study
Abstract
Background: Metformin, an oral biguanide used for the treatment of type-2 diabetes mellitus (DM), has been shown in a considerable number of studies to have...
Abstract 4965: Metformin has an anticancer effect by repressing TWIST/N-cadherin signaling.
Abstract 4965: Metformin has an anticancer effect by repressing TWIST/N-cadherin signaling.
Abstract
Introduction and Objective. Metformin, one of the most commonly used medications for treatment of type 2 diabetes, has emerged as a potential anticancer age...
Preparation and barrier properties of the microcapsules added nanoclays in the wall
Preparation and barrier properties of the microcapsules added nanoclays in the wall
AbstractPreparation of microcapsules applied to the fabrication of self‐healing composites has attracted a lot of attention. However, the leakage of core material from the microcap...
Metformin Inhibits Na+/H+ Exchanger NHE3 Resulting in Intestinal Water Loss
Metformin Inhibits Na+/H+ Exchanger NHE3 Resulting in Intestinal Water Loss
Glycemic control is the key to the management of type 2 diabetes. Metformin is an effective, widely used drug for controlling plasma glucose levels in diabetes, but it is often the...
Metformin and Exercise in Type 2 Diabetes
Metformin and Exercise in Type 2 Diabetes
OBJECTIVE
To determine the effect of metformin on the acute metabolic response to submaximal exercise, the effect of exercise on plasma metformin concentrations, ...
Preparation and Characterization of Microencapsulated Ethylenediamine with Epoxy Resin for Self-healing Composites
Preparation and Characterization of Microencapsulated Ethylenediamine with Epoxy Resin for Self-healing Composites
AbstractHealing agent microcapsules have been used to realize self-healing for polymeric composites. In this work a novel kind of microcapsules encapsulating ethylenediamine (EDA) ...
Abstract 1682: Metformin synergistically enhances antitumor efficacy of sorafenib in vitro
Abstract 1682: Metformin synergistically enhances antitumor efficacy of sorafenib in vitro
Abstract
Background: Previously, we observed anti-tumor effect of sorafenib in osteosarcoma cells. However, a number of studies suggested that cancer cells might esc...

